P/E ratio for Vanda Pharmaceuticals (VNDA)

P/E ratio history for Vanda Pharmaceuticals from 2006 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Novartis NVS	27.8	51.77%	🇨🇭 Switzerland
Eli Lilly LLY	138	654.93%	🇺🇸 USA
Johnson & Johnson JNJ	11.0	-39.66%	🇺🇸 USA
Bristol-Myers Squibb BMY	14.7	-19.83%	🇺🇸 USA
Pfizer PFE	13.5	-26.16%	🇺🇸 USA
Titan Pharmaceuticals TTNP	-6.89	-137.68%	🇺🇸 USA
Merck MRK	54.8	199.61%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.